KR20230043887A - 피리다진 유도체 유리 염기의 결정 형태, 및 이의 제조 방법 및 이의 용도 - Google Patents

피리다진 유도체 유리 염기의 결정 형태, 및 이의 제조 방법 및 이의 용도 Download PDF

Info

Publication number
KR20230043887A
KR20230043887A KR1020237005311A KR20237005311A KR20230043887A KR 20230043887 A KR20230043887 A KR 20230043887A KR 1020237005311 A KR1020237005311 A KR 1020237005311A KR 20237005311 A KR20237005311 A KR 20237005311A KR 20230043887 A KR20230043887 A KR 20230043887A
Authority
KR
South Korea
Prior art keywords
diffraction
crystalline form
diffraction peaks
peaks
peak
Prior art date
Application number
KR1020237005311A
Other languages
English (en)
Korean (ko)
Inventor
준펑 두
린송 구오
Original Assignee
상하이 한서 바이오메디컬 컴퍼니 리미티드
장쑤 한서 파마슈티칼 그룹 캄파니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상하이 한서 바이오메디컬 컴퍼니 리미티드, 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 filed Critical 상하이 한서 바이오메디컬 컴퍼니 리미티드
Publication of KR20230043887A publication Critical patent/KR20230043887A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020237005311A 2020-07-24 2021-07-23 피리다진 유도체 유리 염기의 결정 형태, 및 이의 제조 방법 및 이의 용도 KR20230043887A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010725075 2020-07-24
CN202010725075.1 2020-07-24
PCT/CN2021/108103 WO2022017494A1 (zh) 2020-07-24 2021-07-23 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用

Publications (1)

Publication Number Publication Date
KR20230043887A true KR20230043887A (ko) 2023-03-31

Family

ID=79728520

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237005311A KR20230043887A (ko) 2020-07-24 2021-07-23 피리다진 유도체 유리 염기의 결정 형태, 및 이의 제조 방법 및 이의 용도

Country Status (6)

Country Link
JP (1) JP2023534492A (zh)
KR (1) KR20230043887A (zh)
CN (1) CN115667246A (zh)
CA (1) CA3186000A1 (zh)
TW (1) TW202214603A (zh)
WO (1) WO2022017494A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
WO2023076161A1 (en) 2021-10-25 2023-05-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220766T1 (hr) * 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
BR112019020163A2 (pt) * 2017-03-30 2020-04-22 Bristol-Myers Squibb Company forma cristalina de 6-(ciclopropanocarboxamido)-4-((2-metóxi-3-(1-metil-1h-1,2,4-triazol-3-il)fenil)amino)-n-(metil-d3) piridazina-3-carboxamida
CN115448910B (zh) * 2019-01-28 2024-04-19 江苏豪森药业集团有限公司 一种哒嗪类衍生物抑制剂、其制备方法和应用
CN111909140A (zh) * 2019-04-12 2020-11-10 明慧医药（杭州）有限公司 作为tyk2抑制剂的杂环化合物及合成和使用方法

Also Published As

Publication number Publication date
CA3186000A1 (en) 2022-01-27
CN115667246A (zh) 2023-01-31
WO2022017494A1 (zh) 2022-01-27
JP2023534492A (ja) 2023-08-09
TW202214603A (zh) 2022-04-16

Similar Documents

Publication Publication Date Title
CN115448910B (zh) 一种哒嗪类衍生物抑制剂、其制备方法和应用
CN111295384B (zh) 双环类衍生物抑制剂、其制备方法和应用
KR102075886B1 (ko) 신규한 피라졸로[3,4-d]피리미딘 화합물 또는 그 염
CN112552294B (zh) 含哌嗪杂环类衍生物抑制剂、其制备方法和应用
CN113166078A (zh) 2-氧代喹唑啉衍生物作为甲硫氨酸腺苷转移酶2a抑制剂
WO2021129824A1 (zh) 新型K-Ras G12C抑制剂
JP2017531679A (ja) キナーゼ阻害剤として有用なインドールカルボキシアミド
TW201400486A (zh) 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒□衍生物
KR20140041583A (ko) Ｌｒｒｋ2 키나제 활성의 억제제
EP3209665B1 (en) Substituted pyrrolotriazine amine compounds as pi3k inhibitors
CN113968846A (zh) 一种哒嗪类衍生物的盐、晶型及其制备方法和应用
KR20230043887A (ko) 피리다진 유도체 유리 염기의 결정 형태, 및 이의 제조 방법 및 이의 용도
JP2024505732A (ja) ピリドピリミジノン系誘導体及びその製造方法と使用
CN111094289A (zh) 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
TW202204344A (zh) 酪胺酸激酶2抑制劑、其製備方法及醫藥用途
CN108947974B (zh) 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
CA2926443A1 (en) Heteroaryl linked quinolinyl modulators of ror.gamma.t
KR20230107271A (ko) 이환식 유도체를 포함하는 억제제 유리염기의 결정형, 이의 제조방법 및 용도
CN113166109A (zh) 氨基吡啶类化合物及其制备方法和用途
TW202023548A (zh) 新穎噻唑衍生物以及其藥用可接受鹽類
CN115803325B (zh) 一种egfr抑制剂及其制备方法和应用
WO2024067744A1 (zh) 杂环取代喹唑啉及其制备方法和应用
CN115960117B (zh) 含硫并环类衍生物抑制剂、其制备方法和应用
RU2807611C2 (ru) Ингибитор, представляющий собой производное пиридазина, способ его получения и его применение
WO2022161447A1 (zh) 二甲酰胺类化合物、其制备方法及其在医药上的应用